Bank of America
RCKTW icon

Bank of America’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

Bank of America’s Portfolio RCKTW Stock Details RCKTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$6 – 8372
2024
Q3 		$6 Buy
+100
New +$8 ﹤0.01% 8083
2023
Q4 		– Sell
-100
Closed -$17 – 8187
2023
Q3 		$17 Buy
+100
New +$16 ﹤0.01% 7586

Other funds holding RCKTW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Bank of America's RCKTW Position: Q4 2024 in Review

Bank of America sold out of Rocket Pharmaceuticals Warrant (RCKTW) in Q4 2024, closing a stake of 100 shares — an estimated $6 sold.

Bank of America first reported a position in RCKTW in Q3 2023 and held it in 2 quarters. The position peaked at $17 in Q3 2023. 10 funds tracked by Wall St. Rank hold RCKTW as of Q4 2024.

  • Bank of America reported no remaining Rocket Pharmaceuticals Warrant position as of Q4 2024 after selling out during the quarter.
  • Bank of America sold 100 Rocket Pharmaceuticals Warrant shares in Q4 2024, an estimated $6.
  • Bank of America first reported a position in Rocket Pharmaceuticals Warrant in Q3 2023 and held it in 2 quarters.
  • Bank of America's Rocket Pharmaceuticals Warrant position peaked at $17 in Q3 2023.
  • 10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.